caplacizumab treatment for acquired thrombotic thrombocytopenic purpura

Simona Sica, M. Scully, S. R. Cataland, F. Peyvandi, P. Coppo, P. Knöl, J. A. Kremer Hovinga, A. Metjian, J. De La Rubia, K. Pavenski, F. Callewaert, D. Biswas, H. De Winter, R. K. Zeldin

Research output: Contribution to journalArticle

207 Citations (Scopus)


In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti–von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction between von Willebrand factor multimers and platelets. Methods In this double-blind, controlled trial, we randomly assigned 145 patients with TTP to receive caplacizumab (10-mg intravenous loading bolus, followed by 10 mg daily subcutaneously) or placebo during plasma exchange and for 30 days thereafter. The primary outcome was the time to normalization of the platelet count, with discontinuation of daily plasma exchange within 5 days thereafter. Key secondary outcomes included a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the trial treatment period; recurrence of TTP at any time during the trial; refractory TTP; and normalization of organ-damage markers.
Original languageEnglish
Pages (from-to)335-346
Number of pages12
JournalNew England Journal of Medicine
Publication statusPublished - 2019


  • caplacizumab treatment for acquired


Dive into the research topics of 'caplacizumab treatment for acquired thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this